|
1
|
Martinez Trufero J, Capdevilla J, Cruz JJ
and Isla D: SEOM clinical guidelines for the treatment of thyroid
cancer. Clin Transl Oncol. 13:574–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lundgren CI, Hall P, Dickman PW and
Zedenius J: Clinically significant prognostic factors for
differentiated thyroid carcinoma: A population-based, nested
case-control study. Cancer. 106:524–531. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moo TA, McGill J, Allendorf J, Lee J,
Fahey T III and Zarnegar R: Impact of prophylactic central neck
lymph node dissection on early recurrence in papillary thyroid
carcinoma. World J Surg. 34:1187–1191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scheumann GF, Gimm O, Wegener G,
Hundeshagen H and Dralle H: Prognostic significance and surgical
management of locoregional lymph node metastases in papillary
thyroid cancer. World J Surg. 18:559–567. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suh YJ, Kwon H, Kim SJ, Choi JY, Lee KE,
Park YJ, Park DJ and Youn YK: Factors affecting the locoregional
recurrence of conventional papillary thyroid carcinoma after
surgery: A retrospective analysis of 3381 Patients. Ann Surg Oncol.
22:3543–3549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Podnos YD, Smith D, Wagman LD and
Ellenhorn JD: The implication of lymph node metastasis on survival
in patients with well-differentiated thyroid cancer. Am Surg.
71:731–734. 2005.PubMed/NCBI
|
|
8
|
Randolph GW, Duh QY, Heller KS, LiVolsi
VA, Mandel SJ, Steward DL, Tufano RP and Tuttle RM: American
Thyroid Association Surgical Affairs Committee's Taskforce on
Thyroid Cancer Nodal Surgery: The prognostic significance of nodal
metastases from papillary thyroid carcinoma can be stratified based
on the size and number of metastatic lymph nodes, as well as the
presence of extranodal extension. Thyroid. 22:1144–1152. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aboelnaga EM and Ahmed RA: Difference
between papillary and follicular thyroid carcinoma outcomes: An
experience from Egyptian institution. Cancer Biol Med. 12:53–59.
2015.PubMed/NCBI
|
|
10
|
Cooper DS, Doherty GM, Haugen BR, Kloos
RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI and
Tuttle RM: American Thyroid Association Guidelines Taskforce:
Management guidelines for patients with thyroid nodules and
differentiated thyroid cancer. Thyroid. 16:109–142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rotstein L: The role of lymphadenectomy in
the management of papillary carcinoma of the thyroid. J Surg Oncol.
99:186–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu XM, Wan Y, Sippel RS and Chen H: Should
all papillary thyroid microcarcinomas be aggressively treated? An
analysis of 18,445 cases. Ann Surg. 254:653–660. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sawka AM, Brierley JD, Tsang RW, Thabane
L, Rotstein L, Gafni A, Straus S and Goldstein DP: An updated
systematic review and commentary examining the effectiveness of
radioactive iodine remnant ablation in well-differentiated thyroid
cancer. Endocrinol Metab Clin North Am. 37457–480. (x)2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giordano D, Valcavi R, Thompson GB,
Pedroni C, Renna L, Gradoni P and Barbieri V: Complications of
central neck dissection in patients with papillary thyroid
carcinoma: Results of a study on 1087 patients and review of the
literature. Thyroid. 22:911–917. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Conzo G, Calò PG, Sinisi AA, De Bellis A,
Pasquali D, Iorio S, Tartaglia E, Mauriello C, Gambardella C,
Cavallo F, et al: Impact of prophylactic central compartment neck
dissection on locoregional recurrence of differentiated thyroid
cancer in clinically node-negative patients: A retrospective study
of a large clinical series. Surgery. 155:998–1005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JH, Lee ES and Kim YS:
Clinicopathologic significance of BRAF V600E mutation in papillary
carcinomas of the thyroid: A meta-analysis. Cancer. 110:38–46.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK,
Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, et al: The association of
the BRAF(V600E) mutation with prognostic factors and poor clinical
outcome in papillary thyroid cancer: A meta-analysis. Cancer.
118:1764–1773. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Basolo F, Torregrossa L, Giannini R,
Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A
and Miccoli P: Correlation between the BRAF V600E mutation and
tumor invasiveness in papillary thyroid carcinomas smaller than 20
millimeters: Analysis of 1060 cases. J Clin Endocrinol Metab.
95:4197–4205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tufano RP, Teixeira GV, Bishop J, Carson
KA and Xing M: BRAF mutation in papillary thyroid cancer and its
value in tailoring initial treatment: A systematic review and
meta-analysis. Medicine. 91:274–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alzahrani AS and Xing M: Impact of lymph
node metastases identified on central neck dissection (CND) on the
recurrence of papillary thyroid cancer: Potential role of BRAFV600E
mutation in defining CND. Endocr Relat Cancer. 20:13–22. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito Y, Yoshida H, Maruo R, Morita S,
Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, et
al: BRAF mutation in papillary thyroid carcinoma in a Japanese
population: Its lack of correlation with high-risk
clinicopathological features and disease-free survival of patients.
Endocr J. 56:89–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fugazzola L, Mannavola D, Cirello V,
Vannucchi G, Muzza M, Vicentini L and Beck-Peccoz P: BRAF mutations
in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf).
61:239–243. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Walts AE, Mirocha JM and Bose S:
Follicular variant of papillary thyroid carcinoma (FVPTC):
Histological features, BRAF V600E mutation, and lymph node status.
J Cancer Res Clin Oncol. 141:1749–1756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang W, Gu J, Shang J and Wang K:
Correlation analysis on central lymph node metastasis in 276
patients with cN0 papillary thyroid carcinoma. Int J Clin Exp
Pathol. 6:510–515. 2013.PubMed/NCBI
|
|
27
|
Blanchard C, Brient C, Volteau C, Sebag F,
Roy M, Drui D, Hamy A, Mathonnet M, Henry JF and Mirallié E:
Factors predictive of lymph node metastasis in the follicular
variant of papillary thyroid carcinoma. Br J Surg. 100:1312–1317.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Y, Chen C, Chen Z, Jiang J, Chen Y,
Jin L, Guo G, Zhang X and Ye T: Prediction of central compartment
lymph node metastasis in papillary thyroid microcarcinoma. Clin
Endocrinol (Oxf). 81:282–288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sheu SY, Grabellus F, Schwertheim S,
Handke S, Worm K and Schmid KW: Lack of correlation between BRAF
V600E mutational status and the expression profile of a distinct
set of miRNAs in papillary thyroid carcinoma. Horm Metab Res.
41:482–487. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Givens DJ, Buchmann LO, Agarwal AM,
Grimmer JF and Hunt JP: BRAF V600E does not predict aggressive
features of pediatric papillary thyroid carcinoma. Laryngoscope.
124:E389–E393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Walts AE, Mirocha JM and Bose S:
Follicular variant of papillary thyroid carcinoma (FVPTC):
Histological features, BRAF V600E mutation, and lymph node status.
J Cancer Res Clin Oncol. 141:1749–1756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li C, Aragon Han P, Lee KC, Lee LC, Fox
AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, et al: Does
BRAF V600E mutation predict aggressive features in papillary
thyroid cancer? Results from four endocrine surgery centers. J Clin
Endocrinol Metab. 98:3702–3712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zaydfudim V, Feurer ID, Griffin MR and
Phay JE: The impact of lymph node involvement on survival in
patients with papillary and follicular thyroid carcinoma. Surgery.
144:1070–1078. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mulla M and Schulte KM: Central cervical
lymph node metastases in papillary thyroid cancer: A systematic
review of imaging-guided and prophylactic removal of the central
compartment. Clin Endocrinol (Oxf). 76:131–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jara SM, Carson KA, Pai SI, Agrawal N,
Richmon JD, Prescott JD, Dackiw A, Zeiger MA, Bishop JA and Tufano
RP: The relationship between chronic lymphocytic thyroiditis and
central neck lymph node metastasis in North American patients with
papillary thyroid carcinoma. Surgery. 154:1272–1282. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z,
Wang F, Duan Z, Xin S and Zhang J: Hashimoto's thyroiditis as a
risk factor of papillary thyroid cancer may improve cancer
prognosis. Otolaryngol Head Neck Surg. 148:396–402. 2013.
View Article : Google Scholar : PubMed/NCBI
|
